Importantly, dependency on MCL-1 in cancer cells may be exploited for therapeutic gain, and novel agents that specifically target MCL-1 are already undergoing clinical investigation as potential chemotherapeutics in acute myeloid leukemia (AML) and multiple myeloma (MM). Here, MCL1 is linked to acute myeloid leukemia.